Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer

Diqun Chen, Rouxin Zhang, Aosi Xie, Jinpeng Yuan, Jinhai Zhang, Yongjian Huang, Hongxia Zhang, and Feiran Zhang

*Department of Gastrointestinal Surgery, The First Affiliated Hospital of Shantou University Medical College, Shantou, China; †College of Science and Technology, China Three Gorges University, Yichang, China; ‡Department of Abdominal Surgery, Cancer Hospital of Shantou University Medical College, Shantou, China; §Department of Gastrointestinal Surgery, Shantou Guorui Hospital, Shantou, China; ¶Health Care Center, The First Affiliated Hospital of Shantou University Medical College, Shantou, China

**ABSTRACT**

Gastric cancer (GC) is one of the most common and lethal cancers worldwide. The Nudix hydroxylase (NUDT) genes have been reported to play notable roles in tumor progression. However, the role of NUDT10 in GC has not been reported. In this study, we investigated the expression of NUDT10 in GC and its association with clinicopathological characteristics. Quantitative real-time polymerase chain reaction and analyses of The Cancer Genome Atlas and Human Protein Atlas databases were performed to determine NUDT10 mRNA and protein expression. Receiver operating characteristic curve analysis was used to assess the diagnostic value of NUDT10 in patients with GC. We used Cox regression and the Kaplan–Meier method to assess the correlations between clinicopathological factors and survival outcomes of patients with GC. Gene set enrichment analysis (GSEA) was performed to identify the underlying signaling pathways. NUDT10 mRNA and protein expression was significantly lower in GC tissues compared to normal tissues. Interestingly, higher NUDT10 expression was correlated with advanced tumor stage, deeper local invasion, and worse survival outcomes. Patients with higher NUDT10 expression had a significantly worse prognosis than those with lower NUDT10 expression. Multivariate analysis showed that high NUDT10 expression was an independent predictor of survival outcome. Several pathways, including mismatch repair, nucleotide excision repair, extracellular matrix receptor interaction, and cancer signaling, were identified as enriched pathways in GC through GSEA. To our knowledge, this study is the first to characterize NUDT10 expression in GC. Our study demonstrates that NUDT10 is a promising independent biomarker for GC prognosis.

**Introduction**

Gastric cancer (GC) is the fifth most common neoplasm and third leading cause of cancer-related deaths worldwide, and over a million new cases of GC are diagnosed each year [1]. Although its incidence has steadily declined over the past 50 years, the five-year overall survival rate of GC remains low due to the delay in diagnosis [2]. GC is highly aggressive and typically asymptomatic, and the majority of patients with GC are diagnosed at an advanced stage and with distant metastasis [3]. Therefore, novel effective biomarkers are urgently required for the early detection and precise prognosis of patients with GC.

Nudix hydroxylases (NUDTs) are a family of Mg$^{2+}$-requiring enzymes found in all classes of organisms that catalyze the hydrolysis of a wide range of nucleoside pyrophosphates linked to other moieties of amino acids [4]. All NUDTs consist of a Nudix hydroxylase fold and Nudix box, which is a conserved 23-residue sequence motif(GXXXXXEXXXEXREUXEXGU, where U is a hydrophobic residue and X is any amino acid) [5]. During the process of eliminating hydrolytic substrates, NUDT plays a signaling and regulatory role in metabolism [6]. NUDT members have been reported to participate in the development and progression of several malignancies, including leukemia, renal, breast, and prostate cancers, which are associated with adverse...
outcomes [7–10]. Several genome-wide association studies have indicated that NUDT10, a member of the NUDT family located in Xp11.22, is associated with overall survival in prostate cancer [11–13]. A recent study has implicated that low expression of NUDT10 can increase promoter methylation in prostate cancer, exhibiting a tumor suppressor characteristic [14]. However, the specific role of NUDT10 in GC remains unknown.

Considering the roles of NUDT family members in tumor progression reported in previous studies, we speculate that NUDT10 might have potential oncogenic peculiarity in GC. In this study, we aimed to explore the clinicopathological significance and prognostic value, as well as the underlying molecular signaling pathways of NUDT10 in GC.

Materials and methods

Tumor samples

GC and corresponding adjacent nontumor tissues (50 pairs) were collected from patients who underwent surgery at the First Affiliated Hospital of Shantou University Medical College between 2019 and 2020. All specimens were immediately frozen after surgery and stored at −80°C. This study was approved by the Institutional Research Ethics Committee of the First Affiliated Hospital of Shantou University Medical College. All patients who participated in this study provided written informed consent before surgery.

Data mining

The gene expression quantification (workflow type: high-throughput sequencing [HTSeq]-Counts; 375 cancer and 32 normal samples included) and corresponding clinical data with survival time of patients with GC were obtained from the Genomic Data Commons data portal of The Cancer Genome Atlas (TCGA; https://portal.gdc.cancer.gov/repository; public data updated until 7 April 2020). Boxplots were used to visualize the distribution of the discrete clinical variates. Using this HTSeq-Count data of the gene expression of 375 patients with GC, we analyzed the correlation between the NUDT10 expression level and the clinical factors and survival outcomes for patients with GC. The Human Protein Atlas (HPA; https://www.proteinatlas.org/) project contains an expression map of the complete human proteome in normal and cancerous tissues with distribution information of more than 20,000 human proteins [15]. Further validation of the protein expression difference was conducted through the analysis of immunohistochemistry images obtained from this database. The Kaplan–Meier Plotter database (http://kmplot.com/), which summarizes the gene expression and survival correlation of various cancer types [16], including gastric cancer (https://kmplot.com/analysis/index.php?p=service&cancer=gastric), was used to verify the prognostic ability of NUDT10.

Quantitative real-time polymerase chain (qPCR) reaction

RNA was extracted from the tissues using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA) and reverse transcribed to cDNA using the Geneseed® II First Strand cDNA Synthesis Kit (Geneseed, Guangzhou, China). The primers used for NUDT10 amplification were as follows: forward, 5’-GACAGGTGAGCTCTTTCACACTC-3’; reverse, 5’-GGAGTTATG TCTAGGCGACAGTC-3’. For qPCR, a 20-µL reaction containing 10 µL 2x qPCR SYBR-Green 30 master mix (Vazyme Biotech, Nanjing, China), 0.4 µL forward primer (10 µM), 0.4 µL reverse primer (10 µM), and 5 µL cDNA were included in the 20 µL reaction system. All specimens were tested in triplicate. Relative mRNA levels of NUDT10 were normalized to those of GAPDH.

Statistical analyses

Perl Programming Language (v5.30.0) and R (v3.6.3) software were used for data preparation and analysis. The Wilcoxon rank-sum test in the 'limma' R package [17] was used to analyze differentially expressed genes in both the TCGA and validation cohorts between normal and GC tissues. In addition, the relationships between NUDT10 expression and clinicopathologic parameters were evaluated in the TCGA and validation cohorts using the Chi-square test and logistic regression [18]. The receiver operating characteristic (ROC)
curve is a method used to assess the discrimination accuracy of a diagnostic test over the range of possible cutoff points for the predictor variable [19]. The ROC curve was used to evaluate the diagnostic value of NUDT10 for GC. The Kaplan–Meier method and Cox regression analysis were used to evaluate the prognostic value of NUDT10. Statistical significance was set at \( P < 0.05 \).

**Gene set enrichment analysis (GSEA)**

GSEA is a method used to distinguish differential expression of gene sets between subgroups and to explore potential molecular signaling pathways [20]. The phenotype labels of NUDT10 expression data (375 tumor samples) extracted from TCGA were divided into high and low NUDT10 subgroups based on the median values. The phenotype label files and datasets were uploaded to GSEA software. Each analysis was conducted 1000 times for the gene set permutations. Gene sets were defined as enriched only when both the normal \( P \)-value and false discovery rate (FDR) \( q \)-values were less than 0.05.

**Results**

Considering the roles of the NUDT family and NUDT10 in tumor progression reported in previous studies, we hypothesized that NUDT10 might play an important role in the occurrence and development of GC. In this study, we investigated the expression of NUDT10 in GC and its clinical relevance using the TCGA dataset and our own validation cohort. We aimed to explore the clinicopathologic significance, prognostic value, and underlying signaling pathways of NUDT10 in GC.

**NUDT10 is downregulated in gastric cancer**

A total of 407 samples (375 tumor and 32 adjacent nontumor tissues) with corresponding clinical data were identified in the TCGA cohort. Baseline features are shown in Table 1. We determined NUDT10 expression in tumor and adjacent normal samples and paired samples in the TCGA and validation cohorts. The results revealed that NUDT10 expression was significantly lower in GC tissues than in normal tissues (Figure 1(a-c)). To further validate this result at the protein level, we extracted immunohistochemical staining data (with HPA05768 as the antibody) from the HPA database, which are presented in Table 1. A total of 29 samples, including six normal and 23 tumor samples, were obtained. All six normal gastric samples (100%) showed moderate staining with moderate intensity, while only 10 of 23 tumor samples (43.5%) showed moderate staining with moderate intensity. It can be approximately estimated that the staining of NUDT10 is higher in normal glandular cells than in GC cells (Figure 1(e)). This finding is consistent with our NUDT10 results at the mRNA level.

**Association of NUDT10 expression with clinicopathologic factors**

In the TCGA cohort, NUDT10 expression was significantly correlated with tumor grade (\( P = 0.001 \)), T stage (\( P < 0.001 \)), and TNM stage (\( P = 0.002 \)), but was not correlated with age, sex, lymph node metastasis, and distant metastasis (Table 2). Univariate logistic regression indicated that NUDT10 was correlated with some prognostic clinicopathological factors (Table 3). High NUDT10 expression in GC was correlated with T stage (odds ratio [OR] = 16.286 for T2 vs. T1; OR = 20.278 for T3 vs. T1; and OR = 22.000 for T4 vs. T1) and TNM stage (OR = 3.580 for stage II vs. stage I; OR = 2.602 for stage III vs. stage I; and OR = 2.815 for stage IV vs. stage I). Furthermore, in our validation cohort, NUDT10 expression was significantly associated with T stage (OR = 3.886, T4 vs. T1+ T2+ T3), lymph node metastasis (OR = 5.133, yes vs. no), and TNM stage (OR = 19, stage III vs. stage I + II). Other clinical parameters, such as age, sex, grade, and tumor size, were not correlated with NUDT10 expression.

**Diagnostic value of NUDT10 in gastric cancer**

The mRNA expression profiles extracted from the TCGA cohort were subjected to ROC analysis to evaluate the diagnostic accuracy of NUDT10. The area under the ROC curve was 0.761 (95% confidence interval [CI]: 66.6%-82.8%), the sensitivity
was 75.0%, and the specificity was 61.3%, which shows moderate diagnostic value (Figure 2).

**Survival analysis and univariate /multivariate analyses**

Patients with high NUDT10 expression were strongly correlated with worse survival outcomes (Figure 3(a), p= 0.011). Survival analysis of NUDT10 from the Kaplan–Meier Plotter database further confirmed this result (Figure 3(b), p< 0.001). As shown in Table 4, univariate analysis showed that overexpression of NUDT10 was markedly correlated with poor overall patient survival in GC (hazard ratio [HR] = 1.064; 95% CI: 1.0012–1.118; P= 0.0156). We found that age, stage, and TNM classification were significantly associated with poor survival outcomes. As shown in Table 4 and Figure 4, multivariate Cox analysis of the clinicopathologic variables showed that high NUDT10 expression and age were independent risk factors for GC (HR = 1.089; 95% CI: 1.032–1.149, P= 0.0018 and HR = 1.042, 95% CI: 1.021–1.063, P< 0.001, respectively).

**NUDT10-related pathways by GSEA**

GSEA was performed to screen for potential signaling pathways by comparing the high and low

| Clinical factors | Total | % |
|------------------|-------|---|
| Age at diagnosis (year) | 65.8 (35 ~ 90) | |
| Survival time (year) | 1.4 (0 ~ 10.3) | |
| Survival status | | |
| Alive | 131 | 34.9 |
| Death | 244 | 65.1 |
| Gender | | |
| Female | 134 | 35.7 |
| Male | 241 | 64.3 |
| Tumor grade | | |
| G1 | 10 | 2.7 |
| G2 | 137 | 36.5 |
| G3 | 219 | 58.4 |
| Gx | 9 | 2.4 |
| TNM stage | | |
| I | 56 | 14.4 |
| II | 113 | 30.9 |
| III | 165 | 40.5 |
| IV | 41 | 10.1 |
| T classification | | |
| T1 | 19 | 5.1 |
| T2 | 80 | 21.3 |
| T3 | 168 | 44.8 |
| T4 | 100 | 26.7 |
| Tx | 8 | 2.1 |
| M classification | | |
| M0 | 330 | 88.0 |
| M1 | 25 | 6.7 |
| Mx | 20 | 5.3 |
| N classification | | |
| N0 | 112 | 29.9 |
| N1 | 97 | 25.9 |
| N2 | 75 | 20.0 |
| N3 | 74 | 19.7 |
| Nx | 17 | 4.5 |
| HPA datasets | | |
| High or medium staining in IHC | | |
| (6 normal tissue samples) | 6 | 100 |
| High or medium staining in IHC | | |
| (23 cancer tissue samples) | 10 | 43.5 |

Data are expressed as the mean (min–max); x represents unknown. Abbreviations: TCGA, The Cancer Genome Atlas; HPA, Human Protein Atlas; IHC, immunohistochemistry.
As shown in Table 5 and Figure 5, based on normalized enrichment scores, we identified several significantly enriched signaling pathways, including cell cycle, DNA replication, mismatch repair, nucleotide excision repair, extracellular...
known genes

The Discussion

signaling matrix -

matrix (ECM) receptor integration, and cancer signaling (FDR <0.01), that were related to high expression of NUDT10 in GC.

Discussion

The human genome contains 24 NUDT hydrolase genes and at least five pseudogenes [21], but little is known about the role of NUDT genes in the field of oncology. NUDT family members are distinguished by the Nudix box, which is a 23-residue sequence motif that acts as a housecleaning enzyme [22,23]. The typical NUDT reaction produces substances such as phosphate, pyrophosphate, or N-methyl-2-pyrrolidone [24]. As a member of the NUDT family, NUDT10 has been reported to promote cell proliferation, suppress apoptosis, and trigger the loss of tumor suppressor genes [10], which suggest its role as a promoter of cancer development and progression. Our findings are consistent with those of previous studies.

The expression pattern of NUDT10 and its correlation with clinicopathological factors in GC remain unknown. The present study is the first to explore the role and clinical correlations of NUDT10 in GC. We demonstrate that NUDT10 is an independent prognostic factor for patient survival in GC. NUDT10 expression was significantly reduced in tumor tissues compared to normal tissues. High expression of NUDT10 in GC is significantly correlated with lymph node metastasis, TNM stage, and depth of local invasion. ROC curve analysis revealed a moderate diagnostic value for NUDT10 in GC.

We identified several cancer-related significantly enriched signaling pathways, mainly including ECM interaction and repair of genetic alteration, which are related to high NUDT10

Table 2. Association between NUDT10 expression and clinicopathologic factors in the TCGA and validation cohorts.

| NUDT10 expression | TCGA cohort | Total | Low | High | High (%) | χ² | P value |
|-------------------|-------------|-------|-----|------|----------|----|---------|
| Age <65 | 155 | 72 | 83 | 53.5 | 1.433 | 0.231 |
| Age ≥65 | 220 | 116 | 104 | 47.3 | 0.220 | 0.639 |
| Gender Female | 134 | 65 | 69 | 51.5 | 0.020 | 0.824 |
| Gender Male | 241 | 123 | 118 | 49.0 | 0.020 | 0.824 |
| Tumor grade G1 | 10 | 5 | 5 | 50.0 | 14.535 | <0.001*** |
| Tumor grade G2 | 137 | 86 | 51 | 37.2 | 0.020 | 0.824 |
| Tumor grade G3 | 219 | 92 | 127 | 58.0 | 0.020 | 0.824 |
| T stage T1 | 19 | 18 | 1 | 5.30 | 17.825 | <0.001*** |
| T stage T2 | 80 | 43 | 37 | 46.3 | 0.020 | 0.824 |
| T stage T3 | 168 | 77 | 91 | 54.2 | 0.020 | 0.824 |
| T stage T4 | 100 | 45 | 55 | 55.0 | 0.020 | 0.824 |
| LN metastasis Yes | 246 | 119 | 127 | 51.6 | 0.832 | 0.362 |
| LN metastasis No | 112 | 60 | 52 | 46.4 | 0.020 | 0.824 |
| Distant metastasis Yes | 25 | 13 | 12 | 48.0 | 0.020 | 0.824 |
| Distant metastasis No | 330 | 164 | 166 | 50.3 | 0.020 | 0.824 |
| TNM stage Stage I | 56 | 41 | 15 | 26.8 | 14.575 | 0.002** |
| TNM stage Stage II | 113 | 49 | 64 | 56.6 | 0.020 | 0.824 |
| TNM stage Stage III | 165 | 78 | 87 | 52.7 | 0.020 | 0.824 |
| TNM stage Stage IV | 41 | 20 | 21 | 51.2 | 0.020 | 0.824 |

Validation cohort

| Age <65 | 26 | 11 | 15 | 57.7 | 1.282 | 0.238 |
| Age ≥65 | 24 | 14 | 10 | 41.7 | 0.020 | 0.824 |
| Gender Female | 15 | 9 | 6 | 40.0 | 0.857 | 0.355 |
| Gender Male | 35 | 16 | 19 | 54.2 | 0.020 | 0.824 |
| Tumor size <5 cm | 26 | 14 | 12 | 46.2 | 0.321 | 0.571 |
| Tumor size ≥5 cm | 24 | 11 | 13 | 51.2 | 0.725 | 0.395 |
| Tumor grade G1+ G2 | 23 | 13 | 10 | 43.5 | 0.020 | 0.824 |
| Tumor grade G3 | 27 | 12 | 15 | 55.6 | 0.020 | 0.824 |
| T stage T1+ T2+ T3 | 23 | 8 | 15 | 65.2 | 3.945 | 0.047* |
| T stage T4 | 27 | 10 | 17 | 63.0 | 0.020 | 0.824 |
| LN metastasis Yes | 36 | 14 | 22 | 61.1 | 6.349 | 0.012* |
| LN metastasis No | 14 | 11 | 3 | 21.4 | 0.020 | 0.824 |
| TNM stage Stage I/II | 22 | 19 | 3 | 13.6 | 20.779 | <0.001*** |
| TNM stage Stage III | 28 | 6 | 22 | 78.6 | 0.020 | 0.824 |

Comparison was performed using the Chi-square test. Abbreviations: NUDT10: Nudix hydroxylase 10; LN: lymph node.
The ECM is an important component of the tumor microenvironment and plays a key role in tumor progression and patient survival [25]. Zhou L, et al. constructed a novel prognostic signature for GC based on large sequencing data and showed that ECM-receptor interaction is an important platform for the function of prognosis-related differentially expressed genes [26]. Meanwhile, repair of genetic alterations is typically related to function, as shown by the GSEA results. According to previous studies, the function of NUDT might be related to reactive oxygen species

| Clinical features | TCGA cohort | Validation cohort |
|-------------------|-------------|------------------|
| **TCGA cohort**   |             |                  |
| Age <65 VS <65    | 371         | 50               |
| Gender female VS male | 375 | 50               |
| Grade G2 VS G1    | 146         | 50               |
| Grade G3 VS G1    | 228         | 50               |
| T stage T2 VS T1  | 100         |                  |
| T stage T3 VS T1  | 188         |                  |
| T stage T4 VS T1  | 120         |                  |
| LN metastasis Yes VS No | 357 |                  |
| Distant metastasis Yes VS No | 355 |                  |
| TNM stage stage II VS stage I | 164 |                  |
| TNM stage stage III VS stage I | 203 |                  |
| TNM stage stage IV VS stage I | 91  |                  |
| **Validation cohort** |          |                  |
| Age <65 VS <65    | 50          |                  |
| Gender female VS male | 50 |                  |
| Grade G3 VS G1+ G2 | 50          |                  |
| Tumor size ≥5 cm VS <5 cm | 50 |                  |
| T stage T4 VS T1+ T2+ T3 | 50 |                  |
| LN metastasis Yes VS No | 50 |                  |
| TNM stage Stage III VS Stage I/II | 50 |                  |

**Table 3. Logistic regression of NUDT10 expression and clinicopathological parameters in the TCGA and validation cohorts.**

**Figure 2.** Receiver operating characteristic curve analysis for NUDT10 expression in normal and GC tissues in the TCGA cohort.
and substances produced in the process of regular electron transport in cellular oxidative metabolic pathways, such as protein, lipid, and nucleic acid pathways. Reactive oxygen species cause functional or structural abnormalities in cells [27]. Oxidative damage to nucleic acids might induce a mismatch with nucleotides, leading to alterations in gene information. Accumulation of aberrant genomes can cause mutagenesis or cell death. Gene alterations can be altered through the functions of the
NUDT family [28]. Thus, NUDT10 may have both oncogenic and tumor-suppressive functions in human cancer. Based on this, it can be inferred that the aberrant expression of NUDT10 attenuates DNA repair competence and increases genetic alteration, which is an essential step in tumorigenesis. This might explain why NUDT10 is expressed at low levels in GC tissues compared with normal tissues. Conversely, patients with GC who had higher NUDT10 had significantly worse prognosis.

### Table 4. Univariate and multivariate analyses of the correlation between NUDT10 and survival outcome in patients with gastric cancer (GC) in the TCGA cohort.

| parameter    | HR   | 95%CI        | P-value | HR   | 95%CI        | P-value |
|--------------|------|--------------|---------|------|--------------|---------|
| Age          | 1.027| 1.008–1.046  | 0.006** | 1.044| 1.023–1.066  | <0.001***|
| Gender       | 1.484| 0.980–2.247  | 0.062   | 1.587| 1.039–2.424  | 0.032*  |
| Grade        | 1.368| 0.947–1.977  | 0.095   | 1.381| 0.936–2.037  | 0.103   |
| Stage        | 1.535| 1.221–1.931  | <0.001***| 1.244| 0.807–1.918  | 0.323   |
| T            | 1.298| 1.023–1.645  | 0.031*  | 1.097| 0.789–1.527  | 0.582   |
| M            | 2.048| 1.096–3.827  | 0.024*  | 2.375| 1.060–5.325  | 0.036*  |
| N            | 1.267| 1.069–1.502  | 0.006** | 1.146| 0.892–1.472  | 0.287   |
| NUDT10       | 1.639| 1.116–2.406  | 0.011*  | 1.958| 1.370–0.798  | <0.001***|

### Table 5. Enriched gastrocarcinoma-related gene sets.

| Gene set name (KEGG)                  | Size | NES | NOM p-val | FDR q-val |
|---------------------------------------|------|-----|-----------|-----------|
| NUCLEOTIDE_EXCISION_REPAIR            | 44   | −2.14| 0.002     | 0.002     |
| DNA_REPLICATION                        | 36   | −2.13| <0.001    | 0.001     |
| CELL_CYCLE                            | 124  | −2.07| 0.003     | 0.003     |
| MISMATCH_REPAIR                       | 23   | −2.03| <0.001    | 0.005     |
| ECM_Receptor_INTERACTION              | 84   | 2.16 | <0.001    | 0.001     |
| PATHWAYS_IN_CANCER                    | 325  | 1.64 | 0.021     | 0.100     |

Abbreviations: KEGG, Kyoto Encyclopedia of Genes and Genomes.

![Figure 5](image-url) Significantly enriched signaling pathways revealed by gene set enrichment analysis. Genes involved in cell cycle (a), DNA replication (b), mismatch repair (c), nucleotide excision (d), extracellular matrix receptor (e), and pathways in cancer (f) were significantly enriched in NUDT10-related GC.
than those with lower NUDT10. One possible explanation that can be extrapolated from our data is a null mutation, which leads to increased NUDT10 transcription and nonfunctional protein products. Under these conditions, although NUDT10 is highly expressed in tumor tissues, it loses its function in correcting gene alteration, which is consistent with the poor prognosis in the higher NUDT10 subgroup.

The GSEA results showed that NUDT10 was mainly involved in genetic mutation repair and ECM receptor interaction. This result not only validates the characteristics of the NUDT family, but also reveals an underlying crosstalk between NUDT10 and the tumor microenvironment.

In summary, using bioinformatics analysis and our validating cohort, we analyzed the correlation between NUDT10 and the clinical factors and survival outcomes in GC. We firstly found that high expression of NUDT10 is correlated with advanced tumor stage, deeper local invasion, and worse survival outcomes in patients with GC. Nevertheless, there are also several limitations to this study. Firstly, due to the limitation of sample size, our validating result from HPA database is less convincing and more immunohistochemical validation of NUDT10 in gastric cancer are needed. Secondly, our transcriptome data is from TCGA database, combined analysis of multiple transcriptome profiling datasets may possibly provide better association analysis and survival analysis. Finally, as our study is based on bioinformatics analysis, our present study is unable to determine detailed biological mechanisms of NUDT10 in GC, further experimental exploration of NUDT10 is necessary.

Conclusions

Based on bioinformatics analysis of several public databases and validating cohort, we demonstrated that high expression of NUDT10 represented a potential biomarker in GC. Furthermore, the ECM interaction and repair of genetic alteration may be key regulating pathways of NUDT10 expression in GC. More functional experiments and validation of NUDT10 in GC are worth exploring for further studies.

Research highlights

- NUDT10 expression is significantly lower in GC tissues than in normal tissues
- High NUDT10 expression is correlated with advanced tumor stage and deeper invasion
- Extracellular matrix interaction and genetic alteration repair mainly are enriched in GC

Acknowledgements

The authors extend deepest appreciation to Marie Angeline from the Taylor & Francis Editing Services for editing the manuscript.

Data availability statement

The datasets or profiles used in the current study are from several databases, which are available at the following websites:

- TCGA database: https://portal.gdc.cancer.gov/repository
- HPA database: https://www.proteinatlas.org/
- Kaplan-Meier Plotter database: https://kmplot.com/analysis/index.php?p=service&cancer=gastric

Ethics statement

All procedures followed were in accordance with the ethical standards of the Institutional Research Ethics Committee of the First Affiliated Hospital of Shantou University Medical college. Informed consents were obtained from all patients for being included in the study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

The authors received no specific funding for this work.

ORCID

Diquan Chen @ http://orcid.org/0000-0002-0811-6222
Hongxia Zhang @ http://orcid.org/0000-0001-6117-917X

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

[2] Rawla P, Barsouk A. Epidemiology of gastric cancer: global trends, risk factors and prevention. Prz Gastroenterol. 2019;14(1):26–38.

[3] Meyer HJ, Wilke H. Treatment strategies in gastric cancer. Dtsch Arztebl Int. 2011;108(41):698–705. quiz 706.

[4] Bessman MJ. A cryptic activity in the Nudix hydrolase superfamily. Protein Sci. 2019;28(8):1494–1500.

[5] Bessman MJ, Frick DN, O’Handley SF. The MutT proteins or “Nudix” hydrolases, a family of versatile, widely distributed, “housecleaning” enzymes. J Biol Chem. 1996;271(41):25059–25062.

[6] Mildvan AS, Xia Z, Azurmendi HF, et al. Structures and mechanisms of Nudix hydrolases. Arch Biochem Biophys. 2005;433(1):129–143.

[7] Zgheib NK, Akika R, Mahfouz R, et al. NUDT15 and TPMT genetic polymorphisms are related to 6-mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the children’s cancer center of Lebanon. Pediatr Blood Cancer. 2017;64(1):146–150.

[8] Wang Y, Wan F, Chang K, et al. NUDT expression is predictive of prognosis in patients with clear cell renal cell carcinoma. Oncol Lett. 2017;14(5):6121–6128.

[9] Oka K, Suzuki T, Onodera Y, et al. Nudix-type motif 2 in human breast carcinoma: a potent prognostic factor associated with cell proliferation. Int J Cancer. 2011;128(8):1770–1782.

[10] Li W, Gu M. NUDT11 rs5945572 polymorphism and prostate cancer risk: a meta-analysis. Clin Epigenetics. 2015;8(3):3474–3481.

[11] Vijai J, Kirchhoff T, Gallagher D, et al. Genetic architecture of prostate cancer in the Ashkenazi Jewish population. Br J Cancer. 2011;105(6):864–869.

[12] Johansson M, Holmström B, Hincliffe SR, et al. Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: longitudinal study. Int J Cancer. 2012;130(1):129–137.

[13] Lange EM, Salinas CA, Zuhlke KA, et al. Early onset prostate cancer has a significant genetic component. Prostate. 2012;72(2):147–156.

[14] Kamdar S, Isserlin R, Van der Kwast T, et al. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression. Clin Epigenetics. 2019;11(1):54.

[15] Luck K, Kim D-K, Lambourne L, et al. A reference map of the human binary protein interactome. Nature. 2020;580(7803):402–408.

[16] Szasz AM, Lánczky A, Nagy Á, et al. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 2016;7(31):49322–49333.

[17] Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.

[18] Hess AS, Hess JR. Logistic regression. Transfusion. 2019;59(7):2197–2198.

[19] Mandrekar JN. Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010;5(9):1315–1316.

[20] Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.

[21] Kamiya H, Cadena-Amaro C, Dugué L, et al. Recognition of nucleotide analogs containing the 7,8-dihydro-8-oxo structure by the human MTH1 protein. J Biochem. 2006;140(6):843–849.

[22] Xu W, Jones CR, Dunn CA, et al. Gene ytkD o bacillus subtilis encodes an atypical nucleoside triphosphatase member of the nudix hydrolase superfamily. J Bacteriol. 2004;186(24):8380–8384.

[23] Ito R, Hayakawa H, Sekiguchi M, et al. Multiple enzyme activities of Escherichia coli mutT protein for sanitization of DNA and RNA precursor pools. Biochemistry. 2005;44(17):6670–6674.

[24] Fisher DI, Cartwright JL, Harashima H, et al. Characterization of a nudix hydrolase from deinococcus radiodurans with a marked specificity for (deoxy) ribonucleoside 5‘-diphosphates. BMC Biochem. 2004;5:7.

[25] Qiu H, Zhang X, Yu H, et al. Identification of potential targets of triptolide in regulating the tumor microenvironment of stomach adenocarcinoma patients using bioinformatics. Bioengineered. 2021;12(1):4304–4319.

[26] Zhou L, Lu H, Zeng F, et al. Constructing a new prognostic signature of gastric cancer based on multiple data sets. Bioengineered. 2021;12(1):2820–2835.

[27] Duan J, Zhang H, Li S, et al. The role of miR-485-5p/NUDT1 axis in gastric cancer. Cancer Cell Int. 2017;17(1):92.

[28] Nakabeppe Y, Kajitani K, Sakamoto K, et al. MTH1, an oxidized purine nucleoside triphosphatase, prevents the cytotoxicity and neurotoxicity of oxidized purine nucleotides. DNA Repair (Amst). 2006;5(7):761–772.